Novavax RSV Vaccine Fails to Hit Primary Endpoint in Phase III Trial - BioSpace

1. Novavax RSV Vaccine Fails to Hit Primary Endpoint in Phase III Trial  BioSpace
2. Novavax RSV vaccine flunks late-stage study; shares down 63%  Seeking Alpha
3. Novavax shares crater 69% premarket after trial of ResVax misses its main goal  MarketWatch
4. Why HP, Booking Holdings, and Novavax Slumped Today  Motley Fool
5. Novavax (NASDAQ:NVAX) Re-Enters Penny Stock Territory After Respiratory Disease Vaccine Flunks Late-Stage Trial  Benzinga
6. View full coverage on Google News

(CLICK HERE TO READ AND SEE MORE)